BACKGROUND: Circulating Tumor Cells (CTCs) have been described in malignancies of epithelial origin. In this study we examined the detection of CTCs using CellSearch assay in cholangiocarcinoma and gallbladder cancer. METHODS: The clinical outcomes and detection of CTCs were examined in sixteen patients with biliary cancer using the CellSearch assay. Stages of cancer, baseline demographic data and overall survival were evaluated. RESULTS: Thirteen patients had cholangiocarcinoma and three had gallbladder cancer. Using a cut off of two or more CTCs per 7.5 mL of blood, 3/13 cholangiocarcinoma and 1/3 gallbladder cancer patients had detectable CTCs. At 12 months of follow up from time CTC is drawn; 1/4(25%) of patients with positive CTC were alive while 6/12 (50%) of patients with negative CTC remained alive without a significant difference in survival between the two groups. CONCLUSIONS: Our finding that 25% of patients with cholangiocarcinoma and gallbladder cancer have two or more detectable CTCs/7.5 mL is the first report to our knowledge in this disease. Larger patient numbers are needed to determine the prognostic significance of finding CTCs in biliary cancer. Prospective validation of the role of CTC in advanced biliary cancer patients is on going.
BACKGROUND: Circulating Tumor Cells (CTCs) have been described in malignancies of epithelial origin. In this study we examined the detection of CTCs using CellSearch assay in cholangiocarcinoma and gallbladder cancer. METHODS: The clinical outcomes and detection of CTCs were examined in sixteen patients with biliary cancer using the CellSearch assay. Stages of cancer, baseline demographic data and overall survival were evaluated. RESULTS: Thirteen patients had cholangiocarcinoma and three had gallbladder cancer. Using a cut off of two or more CTCs per 7.5 mL of blood, 3/13 cholangiocarcinoma and 1/3 gallbladder cancerpatients had detectable CTCs. At 12 months of follow up from time CTC is drawn; 1/4(25%) of patients with positive CTC were alive while 6/12 (50%) of patients with negative CTC remained alive without a significant difference in survival between the two groups. CONCLUSIONS: Our finding that 25% of patients with cholangiocarcinoma and gallbladder cancer have two or more detectable CTCs/7.5 mL is the first report to our knowledge in this disease. Larger patient numbers are needed to determine the prognostic significance of finding CTCs in biliary cancer. Prospective validation of the role of CTC in advanced biliary cancerpatients is on going.
Authors: Thomas J Guzzo; Brian K McNeil; Trinity J Bivalacqua; Debra J Elliott; Lori J Sokoll; Mark P Schoenberg Journal: Urol Oncol Date: 2009-12-16 Impact factor: 3.498
Authors: A de la Taille; B Muscatelli; M Colombel; H Jouault; S Amsellem; E Mazeman; C C Abbou; D Chopin Journal: Prog Urol Date: 1998-12 Impact factor: 0.915
Authors: Gershon Y Locker; Stanley Hamilton; Jules Harris; John M Jessup; Nancy Kemeny; John S Macdonald; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2006-10-23 Impact factor: 44.544
Authors: Thomas E Witzig; Blaise Bossy; Teresa Kimlinger; Patrick C Roche; James N Ingle; Clive Grant; John Donohue; Vera J Suman; Douglas Harrington; Jose Torre-Bueno; Kenneth D Bauer Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: Denis A Smirnov; Daniel R Zweitzig; Bradley W Foulk; M Craig Miller; Gerald V Doyle; Kenneth J Pienta; Neal J Meropol; Louis M Weiner; Steven J Cohen; Jose G Moreno; Mark C Connelly; Leon W M M Terstappen; S Mark O'Hara Journal: Cancer Res Date: 2005-06-15 Impact factor: 12.701
Authors: G J Bubley; M Carducci; W Dahut; N Dawson; D Daliani; M Eisenberger; W D Figg; B Freidlin; S Halabi; G Hudes; M Hussain; R Kaplan; C Myers; W Oh; D P Petrylak; E Reed; B Roth; O Sartor; H Scher; J Simons; V Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: W Jeffrey Allard; Jeri Matera; M Craig Miller; Madeline Repollet; Mark C Connelly; Chandra Rao; Arjan G J Tibbe; Jonathan W Uhr; Leon W M M Terstappen Journal: Clin Cancer Res Date: 2004-10-15 Impact factor: 12.531
Authors: Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores Journal: Nat Rev Gastroenterol Hepatol Date: 2020-06-30 Impact factor: 46.802
Authors: Ju Dong Yang; Michael B Campion; Minetta C Liu; Roongruedee Chaiteerakij; Nasra H Giama; Hager Ahmed Mohammed; Xiaodan Zhang; Chunling Hu; Victoria L Campion; Jin Jen; Sudhakar K Venkatesh; Kevin C Halling; Benjamin R Kipp; Lewis R Roberts Journal: Hepatology Date: 2015-08-07 Impact factor: 17.425